Short Bowel Syndrome (SBS) Pipeline Analysis, 2022 | Insights into the FDA and EMA Approvals, Clinical Trials, Emerging Therapies | Zealand Pharma (glepaglutide), 9 Meters Biopharma (vurolenatide)

September 30 19:18 2022
Short Bowel Syndrome (SBS) Pipeline Analysis, 2022 | Insights into the FDA and EMA Approvals, Clinical Trials, Emerging Therapies |   Zealand Pharma (glepaglutide), 9 Meters Biopharma (vurolenatide)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 7+ key pharma and biotech companies are working on 7+ pipeline drugs in the Short Bowel Syndrome (SBS) therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Short Bowel Syndrome Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Short Bowel Syndrome Market. 

The Short Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Short Bowel Syndrome Pipeline Analysis

Short Bowel Syndrome Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Short Bowel Syndrome and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Short Bowel Syndrome Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Short Bowel Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Latest Clinical and Commercial Developments in the Short Bowel Syndrome Therapeutics Market 

On September 30, 2022, Zealand Pharma A/S (CVR-no. 20045078,) announced positive results from the its pivotal Phase 3 trial of glepaglutide. Zealand Pharma’s glepaglutide is a long-acting GLP-2 analogue designed for once or twice-weekly subcutaneous delivery via an auto-injector in patients with short bowel syndrome (SBS).

On September 26, 2022, 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced positive final results from the Phase 2 study of vurolenatide and the outcome of its End-of-Phase 2 meeting with the US FDA. Vurolenatide is a proprietary long-acting GLP-1 receptor agonist in development for adults with short bowel syndrome (SBS).

As per DelveInsight, the Short Bowel Syndrome Therapeutics market is expected to increase in the coming years, owing to the increasing prevalence and the launch of emerging therapies.

Learn How the Ongoing Clinical & Commercial Activities will Affect the Short Bowel Syndrome Therapeutic Segment:

Short Bowel Syndrome Therapeutics Landscape

There are approx. 7+ key companies which are developing therapies for Short Bowel Syndrome. Currently, VectivBio AG has its Short Bowel Syndrome drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Short Bowel Syndrome Therapeutic Market include:

• VectivBio

• Zealand Pharma

• 9 Meters Biopharma

• Hanmi Pharmaceutical

• Adocia

• PhaseBio Pharmaceuticals

• Surrozen

• NPS Pharmaceuticals (Acquired by Shire Plc.)

And many others

Short Bowel Syndrome Drugs Covered in the report include:

• Apraglutide (VectivBio AG)

• Glepaglutide (Zealand Pharma)

• Gattex/teduglutide

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Short Bowel Syndrome Current Treatment Patterns

4. Short Bowel Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Short Bowel Syndrome Late Stage Products (Phase-III)

7. Short Bowel Syndrome Mid-Stage Products (Phase-II)

8. Short Bowel Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Short Bowel Syndrome Discontinued Products

13. Short Bowel Syndrome Product Profiles

14. Key Companies in the Short Bowel Syndrome Market

15. Key Products in the Short Bowel Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Short Bowel Syndrome Unmet Needs

18. Short Bowel Syndrome Future Perspectives

19. Short Bowel Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

MELAS Syndrome Market

“MELAS Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the MELAS Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States